FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses
The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
LEGN.US
FAST NEWS: Legend Biotech shares jump on rising cancer drug sales
The latest: Cell therapy company Legend Biotech Corp. (LEGN.US) recorded net sales of $117 million in the second quarter for its Carvykti cancer drug, up 65% from the previous quarter, according to…
LEGN.US
FAST NEWS: Legend Biotech to raise $300 million from share sale
The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by…
LEGN.US
1548.HK
FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday it recorded net sales of approximately $72 million in the first quarter for its Carvykti cancer…
LEGN.US
Genscript Bio Gets Booster from Subsidiary’s New Cancer Drug
The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the marketKey…
InnoCare Revs Up for Next Phase With Strong Results, IPO Plan
Sales of the company’s key Orelabrutinib cancer drug doubled in the first half of the year, contributing to a 142% revenue jump for the period Key Takeaways: InnoCare Pharma’s revenue…
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
